TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

By /

Positive high-level results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO ®.

Scroll to Top